Logo image of ALNY

ALNYLAM PHARMACEUTICALS INC (ALNY) Stock Price, Quote, News and Overview

NASDAQ:ALNY - Nasdaq - US02043Q1076 - Common Stock - Currency: USD

302.46  -1.54 (-0.51%)

After market: 301.36 -1.1 (-0.36%)

ALNY Quote, Performance and Key Statistics

ALNYLAM PHARMACEUTICALS INC

NASDAQ:ALNY (6/10/2025, 8:27:08 PM)

After market: 301.36 -1.1 (-0.36%)

302.46

-1.54 (-0.51%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High310.22
52 Week Low152.3
Market Cap39.44B
Shares130.39M
Float125.05M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE372.21
Earnings (Next)07-30 2025-07-30/bmo
IPO05-28 2004-05-28


ALNY short term performance overview.The bars show the price performance of ALNY in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 10 15 20 25

ALNY long term performance overview.The bars show the price performance of ALNY in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80 100

The current stock price of ALNY is 302.46 USD. In the past month the price increased by 11.94%. In the past year, price increased by 88.58%.

ALNYLAM PHARMACEUTICALS INC / ALNY Daily stock chart

ALNY Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.45 334.73B
AMGN AMGEN INC 14.13 157.78B
GILD GILEAD SCIENCES INC 14.22 136.94B
VRTX VERTEX PHARMACEUTICALS INC N/A 115.95B
REGN REGENERON PHARMACEUTICALS 11.82 56.53B
ARGX ARGENX SE - ADR 100.08 35.14B
ONC BEONE MEDICINES LTD-ADR 6.74 28.50B
BNTX BIONTECH SE-ADR N/A 25.70B
NTRA NATERA INC N/A 22.56B
BIIB BIOGEN INC 8.56 19.85B
INSM INSMED INC N/A 16.56B
SMMT SUMMIT THERAPEUTICS INC N/A 16.40B

About ALNY

Company Profile

ALNY logo image Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,230 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.

Company Info

ALNYLAM PHARMACEUTICALS INC

675 W Kendall St

Cambridge MASSACHUSETTS 02142 US

CEO: John M. Maraganore

Employees: 2230

ALNY Company Website

ALNY Investor Relations

Phone: 16175518200

ALNYLAM PHARMACEUTICALS INC / ALNY FAQ

What is the stock price of ALNYLAM PHARMACEUTICALS INC today?

The current stock price of ALNY is 302.46 USD. The price decreased by -0.51% in the last trading session.


What is the ticker symbol for ALNYLAM PHARMACEUTICALS INC stock?

The exchange symbol of ALNYLAM PHARMACEUTICALS INC is ALNY and it is listed on the Nasdaq exchange.


On which exchange is ALNY stock listed?

ALNY stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ALNYLAM PHARMACEUTICALS INC stock?

39 analysts have analysed ALNY and the average price target is 330.33 USD. This implies a price increase of 9.22% is expected in the next year compared to the current price of 302.46. Check the ALNYLAM PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ALNYLAM PHARMACEUTICALS INC worth?

ALNYLAM PHARMACEUTICALS INC (ALNY) has a market capitalization of 39.44B USD. This makes ALNY a Large Cap stock.


How many employees does ALNYLAM PHARMACEUTICALS INC have?

ALNYLAM PHARMACEUTICALS INC (ALNY) currently has 2230 employees.


What are the support and resistance levels for ALNYLAM PHARMACEUTICALS INC (ALNY) stock?

ALNYLAM PHARMACEUTICALS INC (ALNY) has a support level at 285.55 and a resistance level at 304.57. Check the full technical report for a detailed analysis of ALNY support and resistance levels.


Is ALNYLAM PHARMACEUTICALS INC (ALNY) expected to grow?

The Revenue of ALNYLAM PHARMACEUTICALS INC (ALNY) is expected to grow by 28.41% in the next year. Check the estimates tab for more information on the ALNY EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ALNYLAM PHARMACEUTICALS INC (ALNY) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ALNYLAM PHARMACEUTICALS INC (ALNY) stock pay dividends?

ALNY does not pay a dividend.


When does ALNYLAM PHARMACEUTICALS INC (ALNY) report earnings?

ALNYLAM PHARMACEUTICALS INC (ALNY) will report earnings on 2025-07-30, before the market open.


What is the Price/Earnings (PE) ratio of ALNYLAM PHARMACEUTICALS INC (ALNY)?

ALNYLAM PHARMACEUTICALS INC (ALNY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.09).


What is the Short Interest ratio of ALNYLAM PHARMACEUTICALS INC (ALNY) stock?

The outstanding short interest for ALNYLAM PHARMACEUTICALS INC (ALNY) is 2.94% of its float. Check the ownership tab for more information on the ALNY short interest.


ALNY Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to ALNY. When comparing the yearly performance of all stocks, ALNY is one of the better performing stocks in the market, outperforming 95.12% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ALNY Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to ALNY. The financial health of ALNY is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALNY Financial Highlights

Over the last trailing twelve months ALNY reported a non-GAAP Earnings per Share(EPS) of -2.09. The EPS increased by 22.01% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -6.4%
ROE -233.64%
Debt/Equity 8.88
Chartmill High Growth Momentum
EPS Q2Q%15.38%
Sales Q2Q%20.2%
EPS 1Y (TTM)22.01%
Revenue 1Y (TTM)17.21%

ALNY Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 78% to ALNY. The Buy consensus is the average rating of analysts ratings from 39 analysts.

For the next year, analysts expect an EPS growth of 23.16% and a revenue growth 28.41% for ALNY


Ownership
Inst Owners96.57%
Ins Owners0.38%
Short Float %2.94%
Short Ratio3.27
Analysts
Analysts78.46
Price Target330.33 (9.21%)
EPS Next Y23.16%
Revenue Next Year28.41%